The present review offers a comprehensive summary of the current knowledge on the involvement of the cGAS-STING pathway in pulmonary fibrosis, as well as an exploration of cGAS and STING agonists and inhibitors, with a focus on their therapeutic potential for treating pulmonary fibrosis. This evidence concerns the gene STING1 and pulmonary fibrosis.